Wells Fargo & Company MN lifted its position in shares of Five Prime Therapeutics Inc (NASDAQ:FPRX) by 4.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 185,382 shares of the biotechnology company’s stock after buying an additional 7,294 shares during the period. Wells Fargo & Company MN owned about 0.64% of Five Prime Therapeutics worth $7,584,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of FPRX. JPMorgan Chase & Co. boosted its position in shares of Five Prime Therapeutics by 162.9% during the second quarter. JPMorgan Chase & Co. now owns 298,395 shares of the biotechnology company’s stock worth $8,984,000 after buying an additional 184,888 shares during the period. Pictet Asset Management Ltd. boosted its position in Five Prime Therapeutics by 51.4% during the third quarter. Pictet Asset Management Ltd. now owns 468,088 shares of the biotechnology company’s stock valued at $19,150,000 after purchasing an additional 158,863 shares during the last quarter. Artal Group S.A. acquired a new position in Five Prime Therapeutics during the second quarter valued at approximately $4,517,000. Victory Capital Management Inc. boosted its position in Five Prime Therapeutics by 28.9% during the second quarter. Victory Capital Management Inc. now owns 666,440 shares of the biotechnology company’s stock valued at $20,066,000 after purchasing an additional 149,340 shares during the last quarter. Finally, State Street Corp boosted its position in Five Prime Therapeutics by 8.4% during the second quarter. State Street Corp now owns 1,354,597 shares of the biotechnology company’s stock valued at $40,782,000 after purchasing an additional 105,077 shares during the last quarter. 83.66% of the stock is owned by institutional investors.

In other news, Director William R. Ringo sold 1,800 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $40.26, for a total value of $72,468.00. Following the completion of the sale, the director now directly owns 1,200 shares of the company’s stock, valued at $48,312. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director William R. Ringo sold 600 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $45.33, for a total value of $27,198.00. Following the completion of the sale, the director now directly owns 600 shares of the company’s stock, valued at $27,198. The disclosure for this sale can be found here. Company insiders own 6.50% of the company’s stock.

Several brokerages recently commented on FPRX. Zacks Investment Research raised Five Prime Therapeutics from a “sell” rating to a “buy” rating and set a $49.00 price target for the company in a research report on Monday, October 16th. Royal Bank of Canada increased their price target on Five Prime Therapeutics from $41.00 to $50.00 and gave the company an “outperform” rating in a research report on Monday, November 6th. BMO Capital Markets increased their price target on Five Prime Therapeutics from $71.00 to $75.00 and gave the company an “outperform” rating in a research report on Tuesday, November 7th. Jefferies Group reissued a “buy” rating and set a $52.00 price target on shares of Five Prime Therapeutics in a research report on Tuesday, September 12th. Finally, ValuEngine cut Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company’s stock. Five Prime Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $64.00.

Five Prime Therapeutics Inc (FPRX) opened at $21.92 on Friday. Five Prime Therapeutics Inc has a 52-week low of $19.73 and a 52-week high of $52.98. The company has a market capitalization of $634.15, a P/E ratio of -4.32 and a beta of 3.90.

Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($1.54) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.35) by ($0.19). Five Prime Therapeutics had a negative net margin of 408.42% and a negative return on equity of 41.57%. The business had revenue of $8.33 million during the quarter, compared to analyst estimates of $16.16 million. During the same period in the previous year, the business earned ($0.72) earnings per share. The business’s quarterly revenue was up 24.7% on a year-over-year basis. equities research analysts anticipate that Five Prime Therapeutics Inc will post -5.56 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://theolympiareport.com/2017/12/31/wells-fargo-company-mn-purchases-7294-shares-of-five-prime-therapeutics-inc-fprx.html.

Five Prime Therapeutics Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Want to see what other hedge funds are holding FPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Five Prime Therapeutics Inc (NASDAQ:FPRX).

Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.